Histopathological effect of Meloxicam (Preferential COX-2 inhibitor NSAID) on liver and kidney of Rabbit

Paper Details

Research Paper 01/09/2017
Views (341) Download (29)
current_issue_feature_image
publication_file

Histopathological effect of Meloxicam (Preferential COX-2 inhibitor NSAID) on liver and kidney of Rabbit

Abrar Ahmad, Rehana Shah Nawaz, Tofique Ahmed Qureshi, Zaheer Ahmed Nizamani, Naseem Rao, Muhammad Qasim, Akhtar Ali
Int. J. Biosci.11( 3), 148-158, September 2017.
Certificate: IJB 2017 [Generate Certificate]

Abstract

The present study was aimed to evaluate the histopathological effect of meloxicam, a preferential COX-2 inhibitor NSAID on functional status of liver and kidney of rabbit. Meloxicam was administered to rabbits divided in two different treatment groups. Group B and C were given therapeutic (1.5mg/kg b.w.) and double dose (3.0mg/kg b.w.) of meloxicam respectively for seven consecutive days. Control group (A) was left untreated. Histopathological studies of liver and kidneys of rabbits in Group B, treated therapeutic dose showed mild alterations in liver (slight dilation of sinusoids and central vein, with mild kupffer cell proliferation) and kidney (slight dilation in distal convoluted tubules and slight disruption of proximal convoluted tubules) on day 5 post treatment which completely reversed to normal on day 10 post treatment. In contrast, marked alterations in liver (severe necrosis and vacuolation of hepatocytes, disruption of bile duct and severe central vein dilation) and kidney (severe shrinkage of glomerulus with widened bowman’s spaces, vasoconstriction of arterioles, congested and disrupted nuclei of distal convoluted tubules, obliterated lumens of proximal convoluted tubule and mild inflammatory cellular infiltration) were observed at day 5 post treatment in Group C, which were persistent till day 10. It was concluded that the effect of meloxicam is dose and time dependent, which was reversible with therapeutic dose, whereas persistent with double dose.

VIEWS 10

Al Rekabi FM, Abbas DA, Hadi NR. 2009. Effects of subchronic exposure to meloxicam on some hematological, biochemical and liver histopathological parameters in rats. Iraqi Journal of Veterinary Sciences 23(2), 249-254.

Budsberg SC, Cross AR, Quandt JE. 2002. Evaluation of intravenous administration of  Meloxic am for pe rioperative pain management following stifle joint surgery in dogs. American Journal Veterinary Research, 63, 1557–1563. https://doi.org/10.2460/ajvr.2002.63.1557

Burukoglu D, Baycu C, Taplamacioglu F, Sahin E, Bektur E. 2014. Effects of nonsteroidal anti-inflammatory meloxicam on stomach, kidney and liver of rats. Toxicology and Industrial Health. 1-7

Cooper CS, Metcalf KA, Barat CE, Cook JA, Scorpio DG. 2009. Comparison of side effects between buprenorphine and meloxicam used postoperatively in dutch belted rabbits (Oryctolagus cuniculus) Journal of the American Association for Laboratory Animal Science. 48, 279 285.

Ebaid H, Dkhil MA, Danfour MA, Tohamy A, Gabry MS. 2007. Piroxicam induced hepatic and renal histopathologic changes in mice. Libyan Journal of Medicine 2(2), 82-89. https://doi.org/10.4176/070130

Fredholm DV, Carpenter JW, Kukanich B, Kohles M. 2013. Pharmacokinetics of meloxicam in rabbits after oral administration of single and multiple doses. American Journal of Veterinary Research 74(4), 636-641. https://doi.org/10.2460/ajvr.74.4.636

Hawkey C, Kahan A, Steinbruck K, Alegre C, Baumelou E, Begaud B. 1998. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. British Journal of Rheumatology 37(9), 937–945. https://doi.org/10.1093/rheumatology/37.9.937

Kay-Mugford P, Benn SJ, Lamarre J, Conlon P. 2000. In vivo effects of nonsteroidalanti in fla mmatory drugs on cyclooxygenase activity in dogs. American Journal of   Veterinary Research 61(7), 802-810. https://doi.org/10.2460/ajvr.2000.61.802

Mahaprabhu R, Bhandarkar AG, Babulal J, Rahangadale SPK Urkure NV. 2011. Ameliorative Effect of Ocimum sanctum on Meloxicam Induced Toxicity in Wistar Rats. Toxicology International 18(2), 130–136. https://doi.org/10.4103/0971-6580.84265

Mahmood KT, Ashraf M, Ahmad MU. 2010. Eco-Friendly Meloxicam Replaces Eco-Damaging Di clofenac Sodium in Veterinary Practice in South Asia -A Review. Journal of Pharmaceutical Sciences. And Research. 2, 672-685.

Modi CM, Mody SK, Patel HB, Dudhatra GB, Kumar A, Avale M. 2012. Toxicopathological overview of analgesic and anti-inflammatory drugs in animals. Journal of Applied Pharmaceutical Science 2(01), 149-157.

Prakash V, Pain DJ, Cunningham AA, Donald PF, Prakash N, Verma A, Gargi R,  Sivkuma S, Rahmani AR. 2003. Catastrophic collapse of Indian white-backed Gyps bengalensisand long-billed Gyps indicus vulture populations. Biological Conservation 109(3), 381–390. https://doi.org/10.1016/s0006-3207(02)00164-7

Wani AR, Nabi SU, Bhat SA, Shah OS, Kutchy NA, Roy RK. 2014. Pharmacokinetic parameters of meloxicam after its oral administration in goat. Veterinary World. 7(3), 141-145. https://doi.org/10.14202/vetworld.2014.141-145

Wojtulewski JA, Schattenkirchner M, Barcelo P, Leloet X, Bevis PR, Bluhmki E, Distel M. 1996. A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen750 mg Daily in patients with rheumatoid arthritis. British Journal of Rheumatology 35(1), 22-28. www.doi.org/10.1093/rheumatology/35.suppl_1.22

Yukiko T, Sokpong L, Michio U. 1977. In Vitro effects of non-steroidal anti-inflammatory drugs on oxidative phosphorylation in rat liver mitochondria. Biochemical Pharmacology 26(22), 2101-2106. https://doi.org/10.1016/0006-2952(77)90258-1